Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Fortress Biotech stock

Learn how to easily invest in Fortress Biotech stock.

Fortress Biotech Inc is a biotechnology business based in the US. Fortress Biotech shares (FBIO) are listed on the NASDAQ and all prices are listed in US Dollars. Fortress Biotech employs 173 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Fortress Biotech

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – FBIO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Fortress Biotech stock price (NASDAQ: FBIO)

Use our graph to track the performance of FBIO stocks over time.

Fortress Biotech shares at a glance

Information last updated 2022-07-01.
Latest market close$0.80
52-week range$0.77 - $3.81
50-day moving average $0.93
200-day moving average $2.03
Wall St. target price$9.42
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-0.86

Buy Fortress Biotech shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Fortress Biotech stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Fortress Biotech price performance over time

Historical closes compared with the close of $0.8 from 2022-07-01

1 week (2022-06-27) -6.98%
1 month (2022-05-31) -7.13%
3 months (2022-03-31) N/A
6 months (2022-01-04) -69.11%
1 year (2021-07-02) -77.72%
2 years (2020-07-02) -70.26%
3 years (2019-07-03) 1.56
5 years (2017-07-03) 4.7

Fortress Biotech financials

Revenue TTM $81.1 million
Gross profit TTM $-85,658,000
Return on assets TTM -29.69%
Return on equity TTM -85.99%
Profit margin -88.31%
Book value $0.92
Market capitalisation $90.2 million

TTM: trailing 12 months

Fortress Biotech share dividends

We're not expecting Fortress Biotech to pay a dividend over the next 12 months.

Fortress Biotech share price volatility

Over the last 12 months, Fortress Biotech's shares have ranged in value from as little as $0.77 up to $3.81. A popular way to gauge a stock's volatility is its "beta".

FBIO.US volatility(beta: 2.27)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fortress Biotech's is 2.2722. This would suggest that Fortress Biotech's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Fortress Biotech overview

Fortress Biotech, Inc. , a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies.

Frequently asked questions

What percentage of Fortress Biotech is owned by insiders or institutions?
Currently 29.877% of Fortress Biotech shares are held by insiders and 33.805% by institutions.
How many people work for Fortress Biotech?
Latest data suggests 173 work at Fortress Biotech.
When does the fiscal year end for Fortress Biotech?
Fortress Biotech's fiscal year ends in December.
Where is Fortress Biotech based?
Fortress Biotech's address is: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
What is Fortress Biotech's ISIN number?
Fortress Biotech's international securities identification number is: US34960Q1094
What is Fortress Biotech's CUSIP number?
Fortress Biotech's Committee on Uniform Securities Identification Procedures number is: 21976U109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site